Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)

PHASE3RecruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Spironolactone

"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."

DRUG

Placebo

"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."

Trial Locations (1)

67000

RECRUITING

University Hospital, Strasbourg, France, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER